TG Therapeutics Shares Surge Following Positive Phase 1 Data for Briumvi

SentiSense · Published · Updated

TG Therapeutics reported positive Phase 1 data for Briumvi in myasthenia gravis. The company also initiated a Phase 2 trial for Briumvi in this condit...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis